Compared to the control cells, MA242-treated cells exhibited a significant reduction in MDM2 and NFAT1 expression in both cell lines (Figure 1E), suggesting that MA242 effectively targets and suppresses these proteins at the cellular level, highlighting its promise as a potential therapeutic agent for breast cancer. Here, MDM2 is linked to breast carcinoma.